Table 1.
Summary of ropivacaine in cancer treatment.
| Targets/Mechanisms | Efficacies | Refs |
|---|---|---|
| Ras superfamily | Sensitizing vemurafenib and dacarbazine | (44) |
| ITGα2 and ITGβ1 | Inhibiting the proliferation of AGS, and BGC-823 cells Inhibiting proliferation and migration of HCT116 and SW620 cells |
(49, 50) |
| CSCs/Wnt/β-catenin | Inhibiting the proliferation of LSC | (56) |
| Autophagy/VEGF-A/STAT3 | Inhibiting B16 cells xenograft tumor growth | (60) |
| Apoptosis-associated pathways | Inhibiting the proliferation and migration of MDA-MB-231 and A375 cells Inhibiting the invasion and migration of A549 and H520 cells Inhibiting the proliferation and migration of Bel7402 and HLE cells Inhibiting the capillary formation and growth of HLT-EC Inhibiting the proliferation of MDA-MB-468 and SkBr cells and sensitizing 5-FU |
(65, 66, 73–75) |
| Cell arrest | Inhibiting the proliferation and migration of MDA-MB-231 and MCF7 cells Inhibiting the proliferation of HuH7 cells |
(67, 68) |
| ERK1/2 | Inhibiting the proliferation and migration of AGS and HG-27 cells | (80) |
| miR-520a-3p | Inhibiting the proliferation of gastric cancer AGS and BGC-823 cells | (84) |
| miR-27b-3p | Inhibiting MDA-MB-231 cells in-vitro and in-vivo | (85) |
| miR96/MEG2/pSTAT3 | Inhibiting the proliferation of SiHa, Caski cells | (89) |
| Sodium channel | Inhibiting the invasion of SW620 cells | (97, 99) |
| Rac1/JNK/paxillin/FAK | Inhibiting the migration of OE33, ESO26 and FLO-1 cells | (95) |
| NF-κB | Inhibiting the adhesion of HUEVC | (107) |
| MMP-9/Akt/FAK | Inhibiting the invasion of NCI-H838 cells | (104) |
| DNA demethylating | Suppressing tumorigenesis properties | (111) |